2020
The Role of Medical Therapy for Menigniomas
Roque A, Omuro A. The Role of Medical Therapy for Menigniomas. 2020, 201-215. DOI: 10.1007/978-3-030-59558-6_13.Peer-Reviewed Original ResearchSystemic therapyProspective single-arm studyNatural historyCurrent NCCN guidelinesLower relapse rateMajority of patientsSingle-arm studySmall patient populationVaried outcome measuresNCCN guidelinesRefractory meningiomasRepeat surgerySurgical resectionSystemic treatmentLocal therapyMedical therapyProlong survivalRelapse rateSurgical optionsArm studyPatient populationSomatostatin analoguesGrade IGrade IIAntiangiogenic agents
2012
Atypical and anaplastic meningiomas treated with bevacizumab
Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ. Atypical and anaplastic meningiomas treated with bevacizumab. Journal Of Neuro-Oncology 2012, 109: 187-193. PMID: 22544653, DOI: 10.1007/s11060-012-0886-4.Peer-Reviewed Original ResearchConceptsProgression-free survivalVascular endothelial growth factor receptorAnaplastic meningiomasRadiographic responseMedian progression-free survivalBest radiographic responseEfficacy of bevacizumabMonths PFS rateEndothelial growth factor receptorKaplan-Meier statisticsActivity of bevacizumabEffective chemotherapeutic optionsAnti-angiogenic agentsTumor blood volumeMR perfusion studiesGrowth factor receptorPFS ratesStable diseaseBevacizumab therapyOverall survivalRANO criteriaRetrospective reviewSurgical optionsProspective studyAggressive tumors